PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

TECH CENTER 15002 Complete if Known Substitute for form 1449A/PTO 10/037,791 **Application Number** INFORMATION DISCLOSURE January 3, 2002 Filing Date STATEMENT BY APPLICANT Stanley M. Crain First Named Inventor 1614 Art Unit (use as many sheets as necessary) **Examiner Name** James H. Reamer Attorney Docket Number Sheet of 96700/727

			U.S. PATE	NT DOCUMENTS	
Examiner Initials		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number - Kind Code <sup>2</sup> (if known			Figures Appear
248	20	us- 4,582,835	4/15/86	Lewis, et al.	
	21	us- 3,879,555	4/22/75	Pachter, et al.	
	22	us- 4,935,428	6/19/90	Lewis, et al.	
	23	us- 5,834,477	11/10/98	Mioduszewski	
THY	24	us- 4,863,928	9/5/89	Atkinson, et al.	
		US-			
		us-			
	l	US-			
		US-			particularly defining the second second of the second seco
		us-	and the second s		
		US-			* I (a) or arrange colleges to many agreement have the first think of a company and a company
		US-	and the second s		
Die mindle biog ut		us-		Моженского вы под	Mildermanifoliters or no oil 2. George on internation and the continuous conditions a new against the condition of
		us-			
		US-		man and a second control of the cont	
		US-		**************************************	
		us-		THE CONTRACTOR OF THE CONTRACTOR	
		us-		- 1 11100000000000000000000000000000000	
		us-		CONTRACTOR OF THE CONTRACTOR O	
		US-			

and a service of the	FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code 3 - Number 4 - Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6				
		1 400 7 4 1 1 1 200 100 17 13 160 No. 11 18 18 18 18 18 18 18 18 18 18 18 18								
				anne encepe appe pro espapo espa						
		a men. Transport of management and panels		. V Ellis o de de propiet e collect com abras y se sus a gregoria.	,					
		Company and constitution over a second of an experimental of beautifully to the second of the second		A CONTROL OF THE SECOND SHOWS A SECOND SECON						
		. It is the set of the control of th		A feet of Johnson Committee of the Commi						
	hada av		and the second to distribute the second and the second		e de la destinación de las communicacións de la destinación de la companyone de la companyon d					

Examiner Date Signature Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/2002. OMB 0/55/10/31  U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMENCE  Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB.								
Substitute for form 1449B/PTO	Col	mplete if Known	16000					
•	Application Number	10/037,791	75900					
INFORMATION DISCLOSURE	_Filing Date	January 3, 2002						
STATEMENT BY APPLICANT	First Named Inventor	Stanley M. Crain						
OTATEMENT BY ALL CIOANT	Group Art Unit	1614						
(use as many sheets as necessary)	Examiner Name	James H. Reamer						
Sheet 1 of 3	Attorney Docket Number	96700/727	ブ					

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue rumber(s), publisher, city and/or country where published.
HH(	1	Request for Ex Parte Reexamination of U.S. Patent No. RE 36,547.
	2	Request for Ex Parte Reexamination of U.S. Patent No. 5,767,125.
	3	Request for Ex Parte Reexamination of U.S. Patent No. 5,580,876.
	4	Request for Ex Parte Reexamination of U.S. Patent No. 6,362,194
	5	Request for Ex Parte Reexamination of U.S. Patent No. 6,096,756.
washingtoning or article fighth reside.	6	Dum and Herz, 1981, "In vivo Receptor Binding of the Opiate Partial Agonist, Buprenorphine, Correlated with its Agonistic and Antagonistic Actions," Br. J. Pharmac. 74:627-633.
	7	Budd, 1987, "Clinical use of opioid antagonists," Balliere's Clinical Anesthesiology 1(4):993-1011.
Canada Cara and Anna and Canada Cara and Canada Cara and Canada C	8	Goodman & Gilman, 1975, The Pharmacological Basis of Therapeutics, 5th Edition, Macmillan, New York, Chapter 15, p. 273.
	9	Crain & Shen, 1995, Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic co-treatment. Proc. Natl. Acad. Sci. U.S.A. 1995 Nov. 7;92(23):10540-10544.
Hha	10	Konieczko et al. 1988, "Antagonism of morphine-induced respiratory depression with nalmefene," Br. J. Anaesth. 61:318-323.

				-
Examiner (/	1. H/	Date	9/11/12	
Signature /	mes Meann	Considered	114/03	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are requestion to the property of the control number.	U.S. Patent and Trademark Of	PTO/SB/08B (10 ov) use through 10/31/2002. OMB 0651-0031/ fice: U.S. DEPARTMENT OF COMMERCE f information unless it contains a valid OMB	CHANA CONTRACTOR
Substitute for form 1449B/PTO	Coi	mplete if Known	\
	Application Number	10/037,791	
INFORMATION DISCLOSURE	Filing Date	January 3, 2002	]
STATEMENT BY APPLICANT	First Named Inventor	Stanley M. Crain	
OTATEMENT BY ALL EIGHT	Group Art Unit	1614	
(use as many sheets as necessary)	Examiner Name	James H. Reamer	
Sheet 2 of 3	Attorney Docket Number	96700/727	]

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	٦
9HK(	11	Barsan et al. 1989, "Duration of Antagonistic Effects of Nalmefene and Naloxone in Opiate-induced Sedation for Emergency Department Procedures," J. Emerg. Med. 7(2); 155-161.	
1	12	Abu-Elheiga et al. 2001, "Continuous fatty acid oxidation and reduced fat storage in mice lacking Acetyl-coA carboxylase 2," Science 291:2613-16.	
	13	Goodman & Gilman (eds.), 1975, The Pharmacological Basis of Therapeutics, 5th Edition, Macmillan, New York, Chapter 15, "Narcotic Analgesics and Antagonists" (by J.H. Jaffe and W.R. Martin) pages 245-283.	
	14	Budd K., 1985, "The use of the opiate antagonist, naloxone, in the treatment of intractable pain." Neuropeptides. 5(4-6):419-22.	
	15	Attal et al. 1989, "Behavioural evidence for a bidirectional effect of systemic naloxone in a model of experimental neuropathy in the rat." Brain Res. 494(2):276-84.	
	16	Kayser et al. 1981, "Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats." Brain Res. 226(1-2):344-8.	
	17	Kayser et al. 1984, "Further evidence for a bidirectional effect of naloxone on the pain threshold in tolerant and non-tolerant arthritic rats." Neuropeptides. 5(1-3):49-52.	
	18	Malaise & Franchimont, 1987, "Methods of clinical and biological assessment of rheumatoid arthritis." Scand. J. Rheumatol. Suppl. 65:81-4, Review.	
tha	19	Specification of US Patent No. RE 36,547.	
	<del></del>		-

			*****
Examiner Signature	amos Me	ama Date Consider	dered 914/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial f reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

JUL 9 8 200BC 1 1 2002



		TECH CEN	TED LOGOLOG	200				
TECH CENTECH CENTER 1600/2900				ATTY, DOCKET NO. PATIENT				
LIST OF REFERENCES CITED BY REQUESTER				7000-076-999 5,767,125				
I a I	IST &	F REFERENCES CITE	PATENT OWNER					
DEC 0 9 7	DEC 0 6 2002 Use several sheets if necessary)				Albert Einstein College of Medicia	ne of Yesh	iva Universi	ty
<b>k</b>	, ii	<i>y</i>		•	ISSUE DATE		GROL₽	
۴۲.	SH'S				June 16, 1998			
Malie	400						·	
ļ		1	U.S	S. PATENT DOCUM	IENTS	F	l	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
2481	AA	4,582,835	4/15/86	Lewis et al.				
94-17	AH	4,457,933	7/3/84					
ועוי	All	4,437,933	1/3/64	Gordon et al.				1
		, <del>.=</del> ~	FORE	IGN PATENT DOC	UMENTS			
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION
	<u> </u>							YES NO
<u></u>		OTHER R	EFERENCES (	Including Author, Tit	le, Date, Pertinent Pages, Etc.)		<del>.</del>	
SHOP	AB		•	•	ef with naloxone. Sever nesthesia 40:583-586	e resp	iratory d	epression
	AC	Pedersen <i>et al.</i> , 198 buprenorphine," Bri	•		nalgesic in combination	with h	igh dose	
	AD	Bergman et al., 198 antinociceptive assa			nhances buprenorphine i yn. Ther. 291:229-37	n a too	oth pulp	
	AE	Dum and Herz, 1981, "In vivo Receptor Binding of the Opiate Partial Agonist, Buprenorphine, Correlated with its Agonistic and Antagonistic Actions," Br. J. Pharmac. 74:627-633						
	AF	Vaccarino <i>et al.</i> , 193 in combination with	_	_	by normal doses of opio 09	id anta	gonists a	lone and
	AG	Levine <i>et al.</i> , 1988, Invest. 82(5):1574-7		on of pentazoc	ine analgesia by low-do	se nalo	oxone," J	. Clin.
	ΑI	Goodman & Gilman, 1 York, Chapter 15, p. 2	•	aarmacological l	Basis of Therapeutics, 5th l	Edition,	Macmilla	an, New
	AJ	Specification of US	Patent No.	Re 36,547				
HM	Crain & Shen, 1995, Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic co-treatment. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10540-10544							fects of
EXAMINER	16	mos Mear	nn	DATE	CONSIDERED 114/	03		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to owner and requester.								